5th Process Development and Automation for CTx

The Pressure on Cell Therapy Process Development Has Never Been Higher.

Last year, the FDA published over 200 Complete Response Letters. The pattern was clear: most cell therapy rejections stem from CMC, comparability, and manufacturing readiness. Meanwhile, the number cell therapies in the clinic has increased by 13% from 2024 to 2025. This has led to growing pressures to move programs toward the next clinical stage and commercialization.

The science is working, but the processes need to catch up.

That's why the 5th Process Development and Automation for Cell Therapies Summit returns in 2026 - this time in San Diego.

Bringing together Process Development, Analytical Development, QC, and MSAT leaders from early clinical to commercial stage, this is the only industry-led event dedicated exclusively to the process development and automation challenges determining whether your therapy reaches patients.

What's different this year:

• New west coast perspectives: from a fresh pool of San Diego's clinical-stage cell therapy companies joining an established community for the first time.
• Deeper automation focus: reflecting industry demand to learn how leading teams are reducing manual processes, aggregating manufacturing data, and scaling without sacrificing quality.
• Increase Late Stage and Pharma Perspectives: from Bristol Myers Squibb, Regeneron, AstraZeneca and others to support your team with examples of how to reach your next clinical or commercial stage.

URLs
Tickets:[ https://go.evvnt.com/3539434-2?pid=154]()
Brochure: [https://go.evvnt.com/3539434-3?pid=154]()

Time: 8:30 AM - 4:15 PM

Prices:
Conference + Workshop Day - Biotech and Pharma: USD 4397.00,
Conference Only - Biotech and Pharma: USD 3099.00,
Conference + Workshop Day - Academic and Startup: USD 3797.00,
Conference Only - Academic and Startup: USD 2699.00,
Conference + Workshop Day - Service Provider: USD 5297.00,
Conference Only - Service Provider: USD 3799.00

Speakers: Nirnoy Dan, Senior Scientist, AstraZeneca, Jacob Okhovat, Associate Director, Process Development Cell Therapy Development and Operations, AstraZeneca, Lan Le, Senior Director, Aurion Biotech, Benjamin Espen, Principal Engineer - Quality, Avobis Bio, LLC, Vilma Sabinina, Director - Chemistry, Manufacturing, Controls and Analytical Strategy, Bayer, Sudhanshu Shekhar, Principal Scientist, Bristol Myers Squibb, Margot Molander, Process Development Scientist, Bristol Myers Squibb, Sagar Sharma, Scientist, Cabaletta Bio, Yan Li, Senior Director - Process Development, Manufacturing Science and Technology, Cabaletta Bio, Schuyler Mesen, Senior Engineer - Process, Cabaletta Bio, Ben Schilling, Senior Manager, Process Development, Caribou Biosciences, Xiangming Li, Director, Cartesian Therapeutics, Mingxiao He, Director - Bioprocessing and Manufacturing, Eureka Therapeutics, Sreedhar Thirumala, Director, Process Development, Genentech, Mamta Kalra, Vice President - CMC Process and Analytical Development, Immatics, Susan Sun, Associate Director PD, JW Therapeutics, Jimmy Chan, Research Fellow, Olivia Newton-John Cancer Research Institute, Yan Wang, Director, Regeneron Pharmaceuticals, Steven Feldman, Scientific Director and Head of Site, Stanford University